Clinical Trial Update: Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Phase 2]

View source ↗

Summary

Phase 2 dose-response study evaluating NCX 470 versus latanoprost in open-angle glaucoma or ocular hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Latanoprost (Latanoprost)
• NCX-470 (NCX-470)

Snippet

Sponsor: Nicox Ophthalmics, Inc. | Conditions: Glaucoma, Open-Angle, Hypertension, Ocular | Phase 2 | Status: COMPLETED | Results posted: 2022-12-08